SCHEMBL7559919

SCHEMBL7559919

O=C1CC(=O)CC(c2ccsc2)C1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.53
GAA P10253 1/20 0.53
HCAR2 Q8TDS4 1/20 0.43
POLB P06746 2/20 0.39
TP53 P04637 1/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
AKT1 P31749 1/20 0.38
CYP19A1 P11511 1/20 0.37
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
PKM P14618 1/20 0.34
ADORA2B P29275 3/20 0.33
SLC22A12 Q96S37 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4827312 0.76 ESR2 (0.50) HCAR2POLBALDH1A1SMN1; SMN2CYP19A1
SCHEMBL10672428 0.75 MAPT (0.77) MAPTGAAPOLBTP53RECQL
SCHEMBL28343399 0.73 ALDH1A1 (0.40) HCAR2POLBALDH1A1SMN1; SMN2AKT1
SCHEMBL7683263 0.73 HCAR2 (0.39) MAPTGAAHCAR2POLBKMT2A
SCHEMBL22111666 0.73 HCAR2 (0.45) HCAR2POLBKMT2ANPSR1ALDH1A1
Formaldehyde SCHEMBL27083167 0.72 HCAR2 (0.40) GAAHCAR2POLBALDH1A1SMN1; SMN2
SCHEMBL9332756 0.72 ALDH1A1 (0.38) HCAR2POLBALDH1A1SMN1; SMN2AKT1
SCHEMBL18825946 0.70 KDR (0.41) HCAR2POLBALDH1A1SMN1; SMN2AKT1
SCHEMBL562614 0.70 MAPT (1.00) MAPTGAAPOLBTP53RECQL
SCHEMBL3089324 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727923-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA University of Georgia Research Foundation, Inc. (US) 2026-04-22 EP disclosed
US-20260098012-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA UNIV GEORGIA (US) 2026-04-09 US disclosed
WO-2024258904-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-12-19 WO disclosed
US-9593069-B2 Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis NORTHWESTERN UNIVERSITY (US) 2017-03-14 US disclosed
US-9593069-B2 Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis NORTHWESTERN UNIVERSITY (US) 2017-03-14 US disclosed
US-20160039740-A1 Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST 2016-02-11 US disclosed
US-9162968-B2 Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis NORTHWESTERN UNIVERSITY (US) 2015-10-20 US disclosed
US-20140371313-A1 Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST 2014-12-18 US disclosed
US-8722939-B2 Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis NORTHWESTERN UNIVERSITY (US) 2014-05-13 US disclosed
US-20120264765-A1 Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis CAMBRIA PHARMACEUTICALS, INC. (US) 2012-10-18 US disclosed
EP-1229019-A1 PROCESS FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLIC ENAMINONE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2002-08-07 EP disclosed
US-6350749-B1 SODIUM CHANNEL MODULATORS, ANTIARRHYTHMIA AND HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS, ANGINA PECTORIS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-02-26 US disclosed
EP-1057812-A1 AMINOGUANIDINE HYDRAZONE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS THEREOF Takeda Chemical Industries, Ltd. (JP) 2000-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098012-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA CD47, SLC11A2, G6PD MAPT 2146/4885GAA 3614/4885HCAR2 1623/4885
US-20140371313-A1 Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis SMN1; SMN2, HTT, CPT1B MAPT 259/4885GAA 48/4885HCAR2 86/4885
US-20160039740-A1 Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis SMN1; SMN2, HTT, CPT1B MAPT 259/4885GAA 48/4885HCAR2 86/4885
US-20120264765-A1 Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis SMN1; SMN2, HTT, CPT1B MAPT 259/4885GAA 48/4885HCAR2 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.